Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: A phase I trial

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Kottaridis, Panagiotis D ^a   North, Janet ^a   Tsirogianni, Maria ^a   Marden, Chloe ^a   Samuel, Edward R ^a   Jide Banwo, Sam ^a   Grace, Sarah ^a   Lowdell, Mark W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMSACRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; ITRACONAZOLE; LAMIVUDINE; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; APHERESIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL LYSATE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; GOOD CLINICAL PRACTICE; HAPLOIDY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVING DONOR; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CELL LINE; UNITED KINGDOM; WHOLE BODY RADIATION; ADVERSE EFFECTS; CELL TRANSPLANTATION; CLINICAL TRIAL; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; PHYSIOLOGIC MONITORING; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADULT; AGED; CELL TRANSPLANTATION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNITED KINGDOM; YOUNG ADULT;

EID: 84936088673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123416     Document Type: Article

References (13)

1. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxicity activity of peripheral-blood lymphocytes and cancer incidence: an 11- year follow-up study of a general population. Lancet 2000; 356:1795-1799. PMID: 11117911
2. Katodritou E, North J, Kottaridis P, Verrou E, Gastari V, Chadjiaggelidou C, et al. Tumor-primed Natural Killer Cells from Patients with Multiple Myeloma Lyse Autologous, NK-resistant, Bone Marrow-derived Malignant Plasma Cells. Am J Hematology 2001; 86:967-973.
3. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neil E, Saha V, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematology 2001; 117:821-827.
4. North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence for a two-stage process in resting NK cell activation. J Immunology 2007; 178:85-94.
5. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG. Expression of costimulatory molecules on AML blasts may affect duration of first remission. Br J Haematology 2003; 120:442-451. PMID: 12580958
6. Miller JS, Soignier Y, Panoskaltis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057. PMID: 15632206
7. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical NK cells KIR-ligand mismatched natural killer cells after infusion in elderly high-risk AML patients. Blood 2011; 118:3273-9. doi: 10.1182/blood-2011-01-329508 PMID: 21791425
8. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 1:98-107.
9. Rubinitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in children with acute myeloid leukemia. J Clin Oncology 2010; 28:955-959. doi: 10.1200/JCO.2009.24.4590 PMID: 20085940
10. Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107:159-166. PMID: 16150947
11. Sabry M, Tsirogianni M, Bakhsh IA, North J, Sivakumaran J, Giannopoulos K, et al. Leukemic priming of resting NK cells is KIR independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors. J Immunology 2011; 87:6227-6234.
12. Brehym C, Huenecke S, Quaiser A, Betz S, Zimmermann O, Soerensen J, et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS ONE 2011; 6:e27351. doi: 10.1371/journal.pone.0027351 PMID: 22096557
13. Olsen JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GvHD by inhibiting activated, alloreactive T cells while retaining GvT effects. Blood 2010; 115:4293-4301. doi: 10.1182/blood-2009-05-222190 PMID: 20233969